So many companies have developed such
increasingly effective medicines, such as those that treat more hep C strains with far shorter treatment regimens, that Gilead — a pioneer in the field with Sovaldi and Harvoni — is projecting $ 3.5 billion to $ 4 billion in U.S. sales from these kinds of drugs in 2018, a dramatic drop from nearly $ 13 billion in 2015.